Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing

Recruiting · NCT06413212 · Observational (researchers observe without assigning treatment) · Lead sponsor: Liu Huang

Interventions studied

Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.

Age range

18 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

18 to 75 years old, regardless of gender.
Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
Advanced and unresectable malignancy confirmed by biopsy diagnosis.
Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2.
Anticipated survival exceed six months.
At least one measurable lesions (according to RECIST 1.1)
Resistance or intolerance to standard therapy regimens.
Signed informed consent form voluntarily.

Pregnant or lactating women.
Have Participated other clinical trials in six months.
Severe liver dysfunction.
Severe renal dysfunction.
Patients with cognitive disorder, mental diseases and terrible compliance.
Allergic to known chemotherapeutic agents.
Other circumstance not suitable to participate in this trial determined by investigators.

1 location listed.